Reviewed by Reza Lankarani M.D

------------------------------------------------------------

Zooravar et al., Cancer Reports (2025)

https://doi.org/10.1002/cnr2.70194

------------------------------------------------------------

This academic article presents a systematic review and meta-analysis examining the Triglyceride-Glucose (TyG) index in relation to breast cancer. It evaluates the TyG index as a potential indicator for breast cancer risk, progression, and its ability to differentiate between malignant and benign breast lesions. While cohort studies did not establish a strong predictive link for initial breast cancer development, case-control and cross-sectional studies suggested a significant association between elevated TyG index and increased risk. The research highlights the TyG index's utility in distinguishing malignant from benign lesions, proposing its value as an accessible diagnostic tool in clinical settings.

Conclusion

This review strengthens TyG’s role as a metabolic biomarker for BC diagnosis, particularly in distinguishing malignant lesions. While cohort studies refute its utility for risk prediction, TyG reflects tumor-driven metabolic dysfunction with implications for prognosis. For surgical practice, TyG could optimize preoperative stratification and postoperative metabolic management. Future studies should prioritize standardized thresholds and validate TyG in multimodal diagnostic algorithms.

Reza Lankarani M.D